ANAB - ANAPTYSBIO, INC
64.67
2.660 4.113%
Share volume: 901,628
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$62.01
2.66
0.04%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-05-2024 | 11-05-2024 | 02-27-2025 | 05-05-2025 | 08-06-2025 | 11-04-2025 | 03-03-2026 | |
| Assets | |||||||||
| Total Assets | 405.835 M | 427.376 M | 493.418 M | 483.834 M | 422.053 M | 335.250 M | 353.098 M | 364.395 M | |
| Current Assets | 372.420 M | 367.350 M | 448.681 M | 431.876 M | 363.112 M | 291.906 M | 330.650 M | 350.250 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 300.970 M | 278.983 M | 238.536 M | 262.293 M | 241.299 M | 221.412 M | 139.123 M | 73.442 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 53.695 M | 71.821 M | 191.581 M | 123.080 M | 98.637 M | 44.298 M | 109.833 M | 238.196 M | |
| Total Non-current Assets | 15.473 M | 42.646 M | 27.914 M | 35.470 M | 43.021 M | 27.996 M | 7.698 M | 0.000 | |
| Property Plant Equipment | 1.954 M | 1.833 M | 1.728 M | 1.849 M | 1.741 M | 1.628 M | 1.500 M | 1.370 M | |
| Other Assets | 31.461 M | 58.193 M | 43.009 M | 50.109 M | 57.200 M | 41.716 M | 20.948 M | 12.775 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 405.835 M | 427.376 M | 493.418 M | 483.834 M | 422.053 M | 335.250 M | 353.098 M | 364.395 M | |
| Total liabilities | 358.057 M | 417.497 M | 409.051 M | 412.966 M | 388.032 M | 379.983 M | 382.514 M | 327.185 M | |
| Total current liabilities | 32.298 M | 40.420 M | 43.880 M | 45.428 M | 44.037 M | 35.527 M | 38.104 M | 38.625 M | |
| Accounts Payable | 4.582 M | 4.890 M | 3.592 M | 4.002 M | 6.123 M | 3.329 M | 2.893 M | 3.871 M | |
| Other liabilities | 325.759 M | 377.077 M | 365.171 M | 367.538 M | 343.995 M | 344.456 M | 344.410 M | 288.560 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 325.759 M | 377.077 M | 365.171 M | 367.538 M | 343.995 M | 344.456 M | 344.410 M | 288.560 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 47.778 M | 9.879 M | 84.367 M | 70.868 M | 34.021 M | -44.733 M | -29.416 M | 37.210 M | |
| Common stock | 706.434 M | 714.986 M | 821.151 M | 829.890 M | 832.516 M | 792.559 M | 792.710 M | 809.793 M | |
| Retained earnings | -658.032 M | -704.692 M | -737.543 M | -759.327 M | -798.656 M | -837.286 M | -822.173 M | -772.559 M |